000306178 001__ 306178
000306178 005__ 20251125112322.0
000306178 0247_ $$2doi$$a10.1007/s00117-025-01531-0
000306178 0247_ $$2pmid$$apmid:41222668
000306178 0247_ $$2ISSN$$a2731-7048
000306178 0247_ $$2ISSN$$a0033-832X
000306178 0247_ $$2ISSN$$a1432-2102
000306178 0247_ $$2ISSN$$a2731-7056
000306178 037__ $$aDKFZ-2025-02418
000306178 041__ $$aEnglish
000306178 082__ $$a610
000306178 1001_ $$aCantré, Daniel$$b0
000306178 245__ $$aAdded value of sodium MRI in multiparametric MRI for WHO grade II astrocytoma surveillance during "watchful waiting": initial experience.   [Zusätzlicher Nutzen der Natrium-MRT bei multiparametrischer MRT zur Überwachung von WHO Grad II Astrozytomen während beobachtenden Abwartens: erste Erfahrungen]
000306178 260__ $$a[Berlin]$$bSpringer Medizin Verlag GmbH$$c2025
000306178 3367_ $$2DRIVER$$aarticle
000306178 3367_ $$2DataCite$$aOutput Types/Journal article
000306178 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1764066154_3576553
000306178 3367_ $$2BibTeX$$aARTICLE
000306178 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000306178 3367_ $$00$$2EndNote$$aJournal Article
000306178 500__ $$a#LA:E040# / 2025 Nov;65(Suppl 1):126-132
000306178 520__ $$aUnresectable WHO grade II astrocytomas require continuous imaging surveillance. To evaluate whether sodium MRI (23Na-MRI) adds diagnostic value to multiparametric MRI and helps predict progressive disease (PD), patients monitored under a 'watchful waiting' strategy were repeatedly examined.Overall, 18 patients with biopsy-proven WHO grade II astrocytoma (10 female, mean age 42 ± 15 years) were prospectively included after baseline imaging. The imaging protocol comprised morphological MRI (T2 TSE, T2 FLAIR, pre- and post-contrast T1 SE), DSC perfusion MRI (n = 17), and 23Na-MRI (n = 9) at 3 T. At baseline, evaluable 23Na-MRI was available for six patients. The Response Assessment in Neuro-Oncology criteria were used to define PD. Semiquantitative ROI analysis was performed on DSC- and 23Na-MRI. Data were analyzed using the Cox regression model.In 14 patients (78%), PD was found after a mean of 420 ± 354 days. For the endpoint time to progression, univariate Cox regression revealed a hazard ratio (HR) of 1.39 for relative regional cerebral blood volume (rrCBV) in the tumor at baseline, and an HR of 1.29 for relative regional cerebral blood flow (rrCBF) at baseline. The 23Na signal in tumor tissue at baseline, normalized to sodium phantoms, revealed an HR of 0.91.Elevation of rrCBV and rrCBF in the tumor indicates poor prognosis, in line with the literature. 23Na-MRI can be used for WHO grade II astrocytoma surveillance. In some treatment-naïve WHO grade II astrocytomas, an initially high sodium signal seems to be prognostically favorable, contrary to the literature on 23Na-MRI in postoperative aftercare. However, due to the small cohort size with evaluable 23Na-MRI at baseline, evidence is limited. In future, 23Na-MRI may help selecting patients for a 'watchful waiting' strategy.
000306178 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000306178 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000306178 650_7 $$2Other$$a3D radial gradient echo projection imaging sequence
000306178 650_7 $$2Other$$aBrain tumor
000306178 650_7 $$2Other$$aDSC perfusion MRI
000306178 650_7 $$2Other$$aLow grade astrocytoma
000306178 650_7 $$2Other$$aMRI in oncology
000306178 7001_ $$aGemescu, Ioan$$b1
000306178 7001_ $$aGerigk, Lars$$b2
000306178 7001_ $$0P:(DE-He78)054fd7a5195b75b11fbdc5c360276011$$aNagel, Armin M$$b3$$udkfz
000306178 7001_ $$aEssig, Marco$$b4
000306178 7001_ $$aLangner, Sönke$$b5
000306178 7001_ $$0P:(DE-He78)5d10a98475a036b2a1ad3c2316d4b3ab$$aWeber, Marc-Andre$$b6$$eLast author
000306178 773__ $$0PERI:(DE-600)3120921-X$$a10.1007/s00117-025-01531-0$$nSuppl. 1$$p126-132$$tDie Radiologie$$v65$$x2731-7048$$y2025
000306178 909CO $$ooai:inrepo02.dkfz.de:306178$$pVDB
000306178 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)054fd7a5195b75b11fbdc5c360276011$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000306178 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5d10a98475a036b2a1ad3c2316d4b3ab$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000306178 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000306178 9141_ $$y2025
000306178 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-18$$wger
000306178 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-18$$wger
000306178 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-18
000306178 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-18
000306178 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-18
000306178 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-18
000306178 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-18
000306178 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-18
000306178 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-18
000306178 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bRADIOLOGIE : 2022$$d2024-12-18
000306178 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-18
000306178 9202_ $$0I:(DE-He78)E040-20160331$$kE040$$lE040 Med. Physik in der Strahlentherapie$$x0
000306178 9201_ $$0I:(DE-He78)E040-20160331$$kE040$$lE040 Med. Physik in der Strahlentherapie$$x0
000306178 980__ $$ajournal
000306178 980__ $$aVDB
000306178 980__ $$aI:(DE-He78)E040-20160331
000306178 980__ $$aUNRESTRICTED